文献速递造血干细胞移植与细胞治疗

造血细胞移植幸存者的晚期感染并发症:一项基于人群的研究

Late infectious complications in hematopoietic cell transplantation survivors: a population-based study.
PubMed 文献 · Blood Adv · 2020-01-01

研究比较了1992至2009年在华盛顿州接受造血细胞移植(HCT)且存活≥2年的1792例幸存者与5455例非移植癌症患者及16340名普通人群的晚期感染发生率。中位随访7年,HCT幸存者全部感染发生率为每1000人年65.4,高于非移植组的39.6(IRR 1.6,95%CI 1.3-1.9)和普通人群的7.2(IRR 10.0,95%CI 8.3-12.1)。作者建议对HCT幸存者保持对感染的警惕并确保遵循抗菌预防和疫苗接种指南。

要点

  • HCT幸存者晚期全部感染发生率为每1000人年65.4,非移植癌症患者为39.6(IRR 1.6,95%CI 1.3-1.9)。
  • 细菌和真菌感染在HCT幸存者中均比非移植癌症幸存者常见70%(IRR 1.7,P<.01)。
  • 复发史是晚期感染的危险因素,部分感染与慢性移植物抗宿主病史相关。

核心结论

  • HCT幸存者存活≥2年后感染发生率仍高于非移植癌症患者和普通人群,且随时间的相对风险在几乎所有类别中持续显著升高。

研究设计与样本

  • 基于人群的队列研究,纳入1992至2009年在华盛顿州接受治疗且存活≥2年的HCT幸存者1792例,中位年龄46岁,52%为异基因移植,90%为血液系统恶性肿瘤;对照为非移植癌症登记个体5455例和驾驶执照文件人群16340名;基于医院和死亡登记代码,采用泊松回归估计感染发生率比(IRR)及95%CI。

主要发现

  • 中位随访7年,全部感染发生率为HCT幸存者每1000人年65.4 vs 非移植组39.6(IRR 1.6,95%CI 1.3-1.9)vs 驾驶执照人群7.2(IRR 10.0,95%CI 8.3-12.1)。
  • 细菌和真菌感染在HCT vs 非移植癌症幸存者中均常见70%(IRR 1.7,P<.01),病毒感染风险较低(IRR 1.4,P=.07)。
  • 在潜在疫苗可预防病原体中,HCT幸存者 vs 非移植组的IRR为3.0(95%CI 2.1-4.3)。
  • 尽管全部感染发生率随时间下降,但≥5年HCT幸存者几乎所有类别的相对风险相比其他组仍显著升高。
  • 晚期感染的危险因素包括复发史,部分感染还包括慢性移植物抗宿主病史。

临床怎么用

  • 作者建议照护HCT幸存者的提供者应保持对感染的警惕,并确保遵循抗菌预防和疫苗接种指南。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Few studies have compared the incidence of infections occurring ≥2 years after hematopoietic cell transplant (HCT) with other cancer patients and the general population. In this study, ≥2-year HCT survivors who were Washington residents treated from 1992 through 2009 (n = 1792; median age, 46 years; 52% allogeneic; 90% hematologic malignancies) were matched to individuals from the state cancer registry (n = 5455, non-HCT) and driver's license files (n = 16 340; Department of Licensing [DOL]). Based on hospital and death registry codes, incidence rate ratios (IRRs; 95% confidence interval [CI]) of infections by organism type and organ system were estimated using Poisson regression. With 7-year median follow-up, the incidence rate (per 1000 person-years) of all infections was 65.4 for HCT survivors vs 39.6 for the non-HCT group (IRR, 1.6; 95% CI, 1.3-1.9) and 7.2 for DOL (IRR, 10.0; 95% CI, 8.3-12.1). Bacterial and fungal infections were each 70% more common in HCT vs non-HCT cancer survivors (IRR, 1.7; P < .01), whereas the risk for viral infection was lower (IRR, 1.4; P = .07). Among potentially vaccine-preventable organisms, the IRR was 3.0 (95% CI, 2.1-4.3) vs the non-HCT group. Although the incidences of all infections decreased with time, the relative risk in almost all categories remained significantly increased in ≥5-year HCT survivors vs other groups. Risk factors for late infection included history of relapse and for some infections, history of chronic graft-versus-host disease. Providers caring for HCT survivors should maintain vigilance for infections and ensure adherence to antimicrobial prophylaxis and vaccination guidelines.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Foord AM, Cushing-Haugen KL, Boeckh MJ, et al. Late infectious complications in hematopoietic cell transplantation survivors: a population-based study. Blood Adv. 2020. PMID: 32227211. doi:10.1182/bloodadvances.2020001470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。